Solara Active Pharma shares jump nearly 18% from day’s low after Q2 turnaround

Solara Active Pharma Sciences swung to a profit in Q2 FY27, reporting its highest quarterly profit and EBITDA in five years. Revenue rose 33%, while its base business expanded margins and its ibuprofen business neared breakeven.